{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-21-033839","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2021-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.673758+00:00","generated_at":"2026-06-28T22:33:14.675601+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PDS Biotech terminates CFO, hires Hill; completes Phase 2 enrollment in head and neck cancer","bullets":["CFO Seth Van Voorhees terminated without cause Sept 30; CEO Bedu-Addo interim CFO, controller Trochimiuk interim PAO.","Matthew Hill appointed CFO effective Oct 18; salary $350k, 35% bonus, severance 12 mo base, inducement option for 202,800 shares.","Completed enrollment of first stage of CPI-naïve arm in VERSATILE-002 Phase 2 study for HPV16 head and neck cancer.","If >=4 of first 17 patients achieve objective response per RECIST 1.1, arm advances to second stage with total 54 patients; trial with Merck."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-21-033839","json":"https://secwatch.observer/filing/0001140361-21-033839.json","markdown":"https://secwatch.observer/filing/0001140361-21-033839.md","text":"https://secwatch.observer/filing/0001140361-21-033839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/brhc10029650_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T22:33:14.675601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e8bb4bb92","claim":"Matthew Hill was appointed as Chief Financial Officer at PDS Biotechnology Corp.","evidence_excerpt":"On October 4, 2021, the Company entered into an Executive Employment Agreement with Matthew Hill (the “ Employment Agreement ”), pursuant to which Mr. Hill will be appointed as the Company’s Chief Financial Officer, effective as of October 18, 2021 (the “ Effective Date ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9757788f74","claim":"Janetta Trochimiuk changed role as interim principal accounting officer at PDS Biotechnology Corp.","evidence_excerpt":"Janetta Trochimiuk, the Company’s controller, will serve as the interim principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will serve as interim principal accounting officer"},{"label":"Role","value":"interim principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"b97e171e1c","claim":"Frank Bedu-Addo changed role as interim principal financial officer at PDS Biotechnology Corp.","evidence_excerpt":"Frank Bedu-Addo, the Company’s Chief Executive Officer, will serve as the Company’s interim principal financial officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will serve as interim principal financial officer"},{"label":"Role","value":"interim principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"ef0fb5e4de","claim":"Seth Van Voorhees departed as Chief Financial Officer, principal financial officer and principal accounting officer at PDS Biotechnology Corp.","evidence_excerpt":"On September 30, 2021, PDS Biotechnology Corporation (the “ Company ”) delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036121033839/0001140361-21-033839-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Financial Officer, principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}